Physician profile
Ivette Cardenas-Esprit
NPI 1124878202
$938.20
in general payments reported to CMS, 2019-2025
13 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $366 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $282.87 | 2024-2025 | Jynarque |
| Recor Medical INC | $149.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vifor Pharma, INC. | $124.89 | 2024-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $65.72 | 2025 | |
| Ardelyx, INC. | $56.34 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $53.69 | 2024-2025 | Velphoro, Velphoro |
| Cormedix INC. | $51.63 | 2024 | Defencath |
| Travere Therapeutics, INC. | $30.19 | 2025 | |
| Lilly USA, LLC | $28.49 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $25.87 | 2025 | Lupkynis |
| Akebia Therapeutics INC | $23.64 | 2024 | Vafseo |
| Astrazeneca Pharmaceuticals Lp | $23.17 | 2025 | Farxiga |
| Calliditas Therapeutics US INC. | $22.41 | 2025 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivette Cardenas-Esprit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.